Great Point Partners’s Silence Therapeutics SLN Stock Holding History

Great Point Partners’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.38M	Buy	1,020,489 +212,457	+26%	+$1.17M	1.24%	29
2025 Q4	$4.91M	Buy	+808,032	New	+$5.17M	1.59%	23
2022 Q4	–	Sell	-68,915	Closed	-$692K	–	53
2022 Q3	$692K	Sell	68,915 -332,534	-83%	-$3.5M	0.17%	40
2022 Q2	$4.76M	Sell	401,449 -42,994	-10%	-$522K	1.14%	28
2022 Q1	$8.44M	Hold	444,443	–	–	2.04%	20
2021 Q4	$10.6M	Buy	+444,443	New	+$10.3M	2.36%	20

Other funds holding SLN

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Great Point Partners's SLN Position: Q1 2026 in Review

Great Point Partners increased its Silence Therapeutics (SLN) stake by 26% in Q1 2026, buying an estimated $1.17M and bringing the position to 1,020,489 shares worth $5.38M. The position accounts for 1.24% of the portfolio, ranked #29.

Great Point Partners first reported a position in SLN in Q4 2021 and has held it in 6 quarters since. The position peaked at $10.6M in Q4 2021. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

Great Point Partners held 1,020,489 shares of Silence Therapeutics worth $5.38M as of Q1 2026.
Great Point Partners bought 212,457 Silence Therapeutics shares in Q1 2026, an estimated $1.17M.
Silence Therapeutics made up 1.24% of Great Point Partners's portfolio in Q1 2026, its #29 holding.
Great Point Partners first reported a position in Silence Therapeutics in Q4 2021 and has held it in 6 quarters since.
Great Point Partners's Silence Therapeutics position peaked at $10.6M in Q4 2021.
56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.